Prot# ALXN1210-NMO-307: A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Project: Research project

Project Details

StatusFinished
Effective start/end date2/18/21 → 2/17/22

Funding

  • INC Research, LLC (ALXN1210-NMO-307)
  • Alexion Pharmaceuticals, Inc. (ALXN1210-NMO-307)